Loading clinical trials...
Loading clinical trials...
An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
Conditions
Interventions
Rivipansel
Locations
97
United States
University of South Alabama Women's and Children's Hospital
Mobile, Alabama, United States
Arkansas Children's Hospital Research Pharmacy
Little Rock, Arkansas, United States
Arkansas Children's Hospital
Little Rock, Arkansas, United States
UC Davis Medical Center Main Hospital
Sacramento, California, United States
University of California Davis Medical Center
Sacramento, California, United States
Howard University Center for Sickle Cell disease
Washington D.C., District of Columbia, United States
Start Date
December 16, 2015
Primary Completion Date
November 15, 2019
Completion Date
November 15, 2019
Last Updated
February 10, 2021
NCT05170412
NCT06526117
NCT06665997
NCT07431398
NCT07222475
NCT05377372
Lead Sponsor
GlycoMimetics Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions